ArticleFrontiers in public health2025
Cost-effectiveness of semaglutide 2.4 mg versus liraglutide 3 mg for the treatment of obesity in Greece.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a major public health issue associated with significant humanistic and economic burden. In Greece, liraglutide 3.0 mg is currently the only reimbursed pharmacotherapy for obesity, restricted to patients with morbid obesity and selected comorbidities. Semaglutide 2.4 mg has demonstrated superior clinical efficacy in the STEP-8 clinical trial; however, its cost-effectiveness relative to liraglutide requires further investigation to ensure informed reimbursement decision-making. Methods: A state-transition model was developed in Microsoft Excel to evaluate the long-term cost-effectiveness of semaglutide 2.4 mg compared with liraglutide 3.0 mg in adults with obesity (BMI ≥ 35 kg/m Results: Semaglutide 2.4 mg was associated with an incremental mean increase in quality-adjusted life expectancy of 0.09 at modestly incremental higher costs of 1,083 compared with liraglutide 3.0 mg, yielding an incremental cost-effectiveness ratio (ICER) of €12,724 per QALY gained, below the willingness-to-pay threshold of €27,117. Probabilistic sensitivity analysis showed semaglutide dominated liraglutide in 80.8% of simulations (greater QALYs and lower costs) and reached 100% probability of cost-effectiveness at a willingness-to-pay threshold of €9,000 per QALY. Deterministic and scenario analysis identified treatment duration, time horizon, discount rates, and diabetes-related complication costs as key drivers of ICER variability. Conclusions: Semaglutide 2.4 mg is likely to be a cost-effective treatment option compared to liraglutide 3 mg for patients with a BMI ≥ 35 and at least one weight-related comorbidity in Greece.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.